Prevention of Diabetic Foot Ulcers at Primary Care Level
DOI:
https://doi.org/10.17140/DRMTOJ-3-129Keywords:
Diabetic foot ulcer (DFU), Neuropathy, Glycaemic controlAbstract
Diabetic foot ulcer (DFT) prevention is best achieved at primary care level and should begin with education, appropriate protective
footwear, glycaemic control and regular screening for loss of protective sensation. In the west, specialized diabetic or
podiatry clinics may assess and quantify neuropathy with many tools including monofilaments, biothesiometry, corneal confocal
microscopy and nerve conduction studies. Vascular assessment can be done via measuring ankle-brachial index, duplex ultrasound
studies and toe pressure. Other foot assessment may include measuring plantar foot pressure using computerized dynamic foot
studies (computerized insole sensor system). The ability to stratify patients based on risks is carried out on the basis of a thorough
medical and surgical history in conjunction with these measurements thereby allowing clinicians to determine the type of intervention.
Effective strategies for foot ulceration prevention include educating patients, their families, and healthcare workers about
adequate foot care and regular foot examinations along with optimal glycaemic control and smoking cessation. Other effective
clinical interventions may include, foot hygiene, debridement of calluses, management of foot deformities which may at times
require prophylactic foot surgery. Counseling patients regarding daily proper footwear and hygiene should be stressed during each
clinic visit. Educating, screening and managing patients with diabetic foot ulceration and or complications is an essential primary
healthcare strategy to prevent unnecessary morbidity and mortality related to diabetic foot. An integrated (interdisciplinary) approach
including, family physicians with special interest in the diabetic foot, diabetic educators, nurses and family members is a
vital component in this regard.
References
Chammas NK, Hill RLR, Edmonds ME. Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J Diabetes Res. 2016; (2016): 2879809. doi: 10.1155/2016/2879809
Goweda R, Shatla M, Alzaidi A, et al. Assessment of Knowledge and practices of diabetic patients regarding diabetic foot care, in Makkah, Saudi Arabia. Journal of Family Medicine and Health Care. 2017; 3(1): 17-22. doi: 10.11648/j.jfmhc.20170301.14
Kassem A, Alsenbasy M, Nagaah A. Risk factors for diabetic foot: Upper Egypt experience. World Academy of Science, Engineer-ing and Technology, International Science Index, Psychological and Behavioral Sciences. 2015; 9(12): 469.
Pecoraro RE. The non-healing diabetic ulcer – a major cause for limb loss. In: Barbul A, Caldwell MD, et al., eds. Clinical and Experi-mental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York, USA: Wiley-Liss; 1991: 27-43.
Alexiadou K, Doupis J. Management of diabetic foot ulcers. Di-abetes Therapy. 2012; 3(1): 4. doi: 10.1007/s13300-012-0004-9
Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag. 2007; 3(1): 65-76.
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 6(1): 37-53. doi: 10.4239/wjd.v6.i1.37
Ferreira RC, Gonçalez DH, Fonseca Filho JM, Costa MT, San-tin RAL. Mid-foot charcot arthropathy in diabetic patients: com-plication of an epidemic disease. Revista Brasileira de Ortopedia. 2012; 47(5): 616-625. doi: 10.1590/S0102-36162012000500013
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 2015; 6(1): 37- 53. doi: 10.4239/wjd.v6.i1.37
He C, Yang J, Li Y, et al. Comparison of lower extremity ath-erosclerosis in diabetic and non-diabetic patients using multidetec-tor computed tomography. BMC Cardiovascular Disorders. 2014; 14: 125. doi: 10.1186/1471-2261-14-125
Jung JH, Tantry US, Gurbel PA, Jeong YH. Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J. 2015; 39(2): 95-113. doi: 10.4093/dmj.2015.39.2.95
PL Detail-Document. Does my patient with diabetes need an aspirin, statin, ACE inhibitor, or ARB? Pharmacist's Letter 2012; 28(11): 281101.
Yusuf S, Sleight P, Pogue J, et al; The Heart Outcomes Pre-vention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153. doi: 10.1056/ NEJM200001203420301
Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: The Veterans Af-fairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003; 26: 1513-1517. doi: 10.2337/diacare.26.5.1513
Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxi-fylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Tech-nol Assess. 2011; 15(40): 1-210. doi: 10.3310/hta15400
Rendell M, Cariski AT, Hittel N, Zhang P. Cilostazol treatment of claudication in diabetic patients. Curr Med Res Opin. 2002; 18: Submit your article to this journal | https://openventio.org/submit-manuscript/ Review | Volume 3 | Number 1| Mohamed H, et al 479-487.
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 2015; 6(1): 37-53. doi: 10.4239/wjd.v6.i1.37
UK Prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in Rathur & Rajbhandari 61patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. doi: 10.1016/S0140-6736(98)07019-6
The Diabetes Control and Complication Trial Research Group (DCCT). The diabetes control and complications research group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Eng J Med. 1993; 329: 977-986.
Barshes NR, Sigireddi M, Wrobel JS, et al. The system of care for the diabetic foot: objectives, outcomes, and opportunities. Dia-bet Foot Ankle. 2013; 4. doi: 10.3402/dfa.v4i0.21847
Amemiya A, Noguchi H, Oe M, et al. Comparison of gait features between feet with callus or corns and normal feet us-ing motion sensors in people with diabetes and people with-out diabetes. J Diabetes Sci Technol. 2016; 10(2): 614-615. doi: 10.1177/1932296815616135
Bus SA, Waaijman R, Arts M, et al. Effect of custom-made footwear on foot ulcer recurrence in diabetes: A multicenter ran-domized controlled trial. Diabetes Care. 2013; 36(12): 4109-4116. doi: 10.2337/dc13-0996
Waaijman R, Keukenkamp R, de Haart M, et al. Adherence to wearing prescription custom-made footwear in patients with dia-betes at high risk for plantar foot ulceration. Diabetes Care. 2013; 36(6): 1613-1618. doi: 10.2337/dc12-1330
Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vascular Health and Risk Management. 2007; 3(1): 65-76.
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 2015; 6(1): 37-53. doi: 10.4239/wjd.v6.i1.37
Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recom-mendations for cardiovascular disease prevention. Nutrients, 2013; 5(9): 3646-3683. doi: 10.3390/nu5093646
Turan Y, Ertugrul BM, Lipsky BA, Bayraktar K. Does physi-cal therapy and rehabilitation improve outcomes for diabetic foot ulcers? World J Exp Med. 2015; 5(2): 130-139. doi: 10.5493/wjem. v5.i2.130
Kastenbauer T, Sauseng S, Sokol G, Auinger M, Irsigler K. A prospective study of predictors for foot ulceration in type 2 diabe-tes. J Am Podiatry Med Assoc. 2001; 91: 343-350.
Meyer KA, Conigrave KM, Chu NF, et al. Alcohol consump-tion patterns and HbA1c, C-peptide and insulin concentrations in Submit your article to this journal | https://openventio.org/submit-manuscript/ men. J Am Coll Nutr. 2014; 22: 185-194.
Mohamed H. Evidence Based Counseling for Health Care Profession-als. Saarbrücken, Germany: LAP LAMBERT Academic Publish-ing; 2017.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Dermatology (DER) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
